Safety and Effectiveness Profile of Dupilumab in the Treatment of Atopic Dermatitis in Special Populations
Acta Dermato-Venereologica · 2025
DOI: 10.2340/actadv.v105.43523 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Acta Dermato-Venereologica, 2025. Verfasst von Niccolo Gori und 20 weiteren Autor:innen. Beteiligte Einrichtung: Dermatologia, Dipartimento Universitario di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy; Dermatologia, Dipa…. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Antibodies, Monoclonal, Humanized, Dermatologic Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Dupilumab, the first biologic treatment approved for moderate to severe atopic dermatitis, has completely revolutionized the management of such disease allowing long-term control of its clinical signs and symptoms. Nevertheless, data regarding the safety and effectiveness profile of dupilumab in patients belonging to special populations are scarce. This observational, multicentric study analysed the effectiveness and safety profile of dupilumab over 3 years in the treatment of 70 patients with moderate to severe atopic dermatitis and associated comorbidities such as cancers, renal and liver failure, viral chronic infections, and degenerative and autoimmune neurological disorders. Patients achieved a significant improvement in both physician-assessed and patient-reported outcomes after 16 weeks of treatment, with a continuous therapeutic response maintained throughout the 156-week period. The safety profile was comparable to clinical trials and real-world data involving patients without significant comorbidities. In conclusion, the findings support the safety of dupilumab in managing severe atopic dermatitis in fragile patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Dermatologia, Dipartimento Universitario di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy; Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Univ…
- Dermatology Unit, Department of Medicine (DIMED), University of Padua, Padova, Italy.
- Dermatologia, Fondazione Policlinico, Universitario Campus Bio-Medico, Roma, Italy.
- Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy.
- Department of Medical Sciences, Section of Dermatology, University of Turin, Torino, Italy.
- Department of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy; Dermatology Unit, Fondazione Policlinico "Tor Vergata", Rome, Italy.
Zitieren
APA
Gori, N., Sernicola, A., Ippoliti, E., Coppola, R., Maurelli, M., Ortoncelli, M., Paganini, C., Tolino, E., Mariano, M., Del Duca, E., Moretta, G., Panasiti, V., Girolomoni, G., Ribero, S., Boeti, L., Bianchi, L., Fargnoli, M. C., Pellacani, G., Pallotta, S., …, & Galluzzo, M. (2025). Safety and Effectiveness Profile of Dupilumab in the Treatment of Atopic Dermatitis in Special Populations. Acta Dermato-Venereologica. https://doi.org/10.2340/actadv.v105.43523
Vancouver
Gori N, Sernicola A, Ippoliti E, Coppola R, Maurelli M, Ortoncelli M, et al. Safety and Effectiveness Profile of Dupilumab in the Treatment of Atopic Dermatitis in Special Populations. Acta Dermato-Venereologica. 2025. doi:10.2340/actadv.v105.43523
BibTeX
@article{Gori2025,
author = {Gori, Niccolo and Sernicola, Alvise and Ippoliti, Elena and Coppola, Rosa and Maurelli, Martina and Ortoncelli, Michela and Paganini, Claudia and Tolino, Ersilia and Mariano, Maria and Del Duca, Ester and Moretta, Gaia and Panasiti, Vincenzo and Girolomoni, Giampiero and Ribero, Simone and Boeti, Luisa and Bianchi, Luca and Fargnoli, Maria Concetta and Pellacani, Giovanni and Pallotta, Sabatino and Peris, Ketty and Galluzzo, Marco},
title = {Safety and Effectiveness Profile of Dupilumab in the Treatment of Atopic Dermatitis in Special Populations},
journal = {Acta Dermato-Venereologica},
year = {2025},
doi = {10.2340/actadv.v105.43523}
}
EUVIMED